Page 86 - GTM-2-4

Global Translational Medicine Prognosis of relapse in squamous cell lung cancer

period demonstrates the accuracy of predicting relapse, A more substantial difference in the levels of indicators
ranging from 71.9% to 82.5% (Table 7). The accuracy of during the 3 weeks – 6 months post-surgical treatment,
the calculation result for the combined model within this compared with the 3 – 6 months period, carries a higher
specified timeframe is 91.2%. At the same time, PPV is prognostic information value. Within the 3 weeks –
73.3%, NPV is 97.6%, and TV is 0.119. 6 months timeframe, changes in their levels enable the
prediction of the development of relapse within a year after
Table 3. Relationship between the levels of measured treatment with an accuracy ranging from 86.0% – 89.5%,
indicators 3 weeks after surgery and the relapse‑free and for the combined model, the accuracy reaches 96.5%
survival of patients with Stage I–II NSCLC (univariate Cox (Table 8).
proportional hazards model)
4. Discussion
Index HR (95% CI) P
SCC antigen (ng/ml) 1.063 (1.004 – 1.122) 0.038 The scope of tumor resection, denoted as R0, necessitates
CXCR2 (% in lymphocytes) 1.037 (1.005 – 1.069) 0.031 the complete removal of the tumor and any developed
CD44v6 (% in monocytes) 1.019 (1.012 – 1.026) 0.029 metastases. Despite concerted efforts to eliminate tumor
Combined model 1.103 (1.027 – 1.179) 0.019 cells entirely, some may persist in the body. The possibility
of this occurrence is significant, given that even the most
Abbreviations: CI: Confidence interval; HR: Hazards ratio; P: An
indicator of the level of statistical significance of the hazards ratio, advanced research methods may fail to detect these residual
SCC: Squamous cell carcinoma. cells. Therefore, certain patients experience tumor relapses,

Table 4. Difference in postoperative levels of measured parameters in the blood of patients with tumor recurrence
Index Time interval (median [25;75 percentiles])
3 weeks–3 months 3 months–6 months 3 weeks–6 months
SCC (ng/ml) 0.17 (0.16; 0.18) 0.33 (0.31; 0.41) 1 0.52 (0.48; 0.58) 1,2
CXCR2 (% in lymphocytes) 2.85 (2.80; 2.95) 4.25 (4.19; 4.55) 1 7.10 (7.01; 7.68) 1,2
CD44v6 (% in monocytes) 0.40 (0.37; 0.51] 0.60 (0.55; 0.65) 1 1.08 (0.98; 1.15) 1,2
Combined model 0.088 (0.085; 0.093) 0.127 (0.119; 0.138) 1 0.217 (0.205; 0.227) 1,2
Notes: Statistical significance of the difference of indicator levels for a period of 3 – 6 months compared to 3 weeks – 3 months; Statistical significance
2
1
of the differences of indicator levels for a period of 3 weeks – 6 months compared to 3 weeks – 3 months.
Table 5. Cox proportional hazards model of the dependence of relapse‑free survival of patients with NSCLC on the difference in
the level of indicators after surgical treatment
Index Time interval Univariate model Multivariate model
HR (95% CI) P HR (95% CI) P
SCC (ng/ml) 3 weeks – 3 months 1.188 (1.003–1.373) 0.031 1.114 (1.004–1.224) 0.033
3 months – 6 months 1.245 (1.012–1.478) 0.022 1.221 (1.098–1.344) 0.024
3 weeks – 6 months 1.425 (1.037 – 1.813) 0.011 1.367 (1.015 – 1.719) 0.013
CXCR2 (% in lymphocytes) 3 weeks – 3 months 1.025 (1.003 – 1.047) 0.033 1.057 (1.003 – 1.111) 0.034
3 months – 6 months 1.051 (1.005 – 1.097) 0.027 1.071 (1.009 – 1.133) 0.028
3 weeks – 6 months 1.085 (1.008 – 1.162) 0.019 1.099 (1.015 – 1.183) 0.021
CD44v6 (% in monocytes) 3 weeks – 3 months 1.158 (1.025 – 1.291) 0.027 1.111 (1.018 – 1.204) 0.031
3 months – 6 months 1.221 (1.028 – 1.414) 0.025 1.245 (1.029 – 1.461) 0.026
3 weeks – 6 months 1.302 (1.099 – 1.505) 0.020 1.298 (1.079 – 1.517) 0.023
Combined model 3 weeks – 3 months 1.421 (1.102 – 1.740) 0.010 1.315 (1.099 – 1.531) 0.014
3 months – 6 months 1.688 (1.158 – 2.118) 0.008 1.586 (1.118 – 2.051) 0.011
3 weeks – 6 months 1.786 (1.148 – 2.424) 0.007 1.642 (1.107 – 2.177) 0.009
Notes: SCC: Squamous cell carcinoma; HR: Hazards ratio; CI: Confidence interval; P: An indicator of the level of statistical significance of the hazards
ratio.

Volume 2 Issue 4 (2023) 7 https://doi.org/10.36922/gtm.2209